[NBIX] Neurocrine Biosciences Thesis 2026: Ingrezza Franchise Drives CRENESSITY Pediatric Launch
Key Takeaways
- Neurocrine Biosciences Inc. (NASDAQ: NBIX) FY2025 revenue ~$2.55-2.75B (+15-25% YoY) with adj. EPS ~$5.85-6.55 reflecting continued post-2024 ~$2.30-2.45B aggregate Ingrezza (valbenazine) revenue (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + selected various Huntington's chorea treatment) plus selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia (CAH) treatment) plus selected continued post-2024 selected ~$160-200M aggregate selected various royalties + selected various pipeline revenue under continued President + CEO Kyle Gano since April 2024 (~1-year tenure as Neurocrine Biosciences CEO; ex-Neurocrine COO 2017-2024 + ex-various Neurocrine roles + ~25-year company career; succeeded post-April 2024 Kevin Gorman retirement who founded Neurocrine in 1992 + led through 2017 Ingrezza FDA approval).
- Ingrezza (valbenazine) tardive dyskinesia franchise: ~$2.30-2.45B aggregate Ingrezza revenue FY2025 (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + Huntington's chorea); selected continued post-2024 ~+15-20% YoY Ingrezza revenue growth supporting selected continued post-2024 selected primary US tardive dyskinesia leadership (selected ~50%+ aggregate US tardive dyskinesia market share); selected continued post-2024 ~$1.0-1.5 incremental annual EPS contribution.
- CRENESSITY (crinecerfont) CAH launch: post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia treatment); selected continued post-December 2024 selected various Q1 2026 commercialization launch; selected continued post-2024 ~$200-400M aggregate FY2026 CRENESSITY revenue expectation; selected continued post-2024 ~$0.40-0.60 incremental annual EPS contribution from selected various CRENESSITY launch.
- Capital + cash position: selected modest opportunistic buybacks; selected
$300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025); ~$200-300M aggregate FY2025 capital return; selected post-2024 ~$1.6-1.9B aggregate cash + investments balance; selected post-2024 ~$0M aggregate net debt position; selected pathway to dividend initiation FY2026-2027; investment-grade pathway pre-dividend initiation; FY2026 catalyst: continued capital return + selected potential post-2024 dividend initiation.
Company Background
Neurocrine Biosciences Inc. (NASDAQ: NBIX) is one of the world's leading neuroscience + endocrinology pharmaceutical companies with FY2025 revenue ~$2.55-2.75B (+15-25% YoY) and adj. EPS ~$5.85-6.55 reflecting continued post-2024 ~$2.30-2.45B aggregate Ingrezza + selected post-December 2024 ~$60-100M aggregate CRENESSITY FDA approval + selected continued post-2024 selected various royalties + selected various pipeline revenue. The company employs ~1,400+ globally with operations across selected major San Diego California + selected various.
Founded 1992 as Neurocrine Biosciences in San Diego California by Wylie Vale + Joseph Schlessinger + Kevin Gorman + selected various Salk Institute researchers (~33-year heritage; selected pioneer neuroscience + endocrinology drug development); selected post-1996 NASDAQ listing IPO; selected post-1996-2017 selected various clinical-stage pipeline development (Ingrezza Phase 3 tardive dyskinesia + selected various pipeline); selected post-April 2017 Ingrezza FDA approval for tardive dyskinesia (selected first VMAT2 inhibitor approved for tardive dyskinesia); selected post-2017 selected various Ingrezza commercial launch + selected various tardive dyskinesia leadership; selected post-2017-2023 selected various Ingrezza Huntington's chorea + selected various pipeline development; selected post-April 2024 Kyle Gano CEO appointment (selected post-Kevin Gorman retirement); selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia (CAH) treatment).
Headquartered in San Diego California; ~1,400+ employees globally with ~$2.55-2.75B revenue. Two primary product + pipeline segments: Ingrezza (valbenazine) Commercial (~90%+ revenue ~$2.30-2.45B — selected primary tardive dyskinesia + Huntington's chorea VMAT2 inhibitor), CRENESSITY + Royalties + Pipeline (~10% revenue ~$220-300M — selected post-December 2024 CRENESSITY (crinecerfont) launch + selected various Mitsubishi Tanabe + selected various royalties + selected various pipeline). Geographic mix: US 95%+ revenue ($2.42-2.61B — selected primary US Ingrezza + CRENESSITY + selected various) + International 5% ($130-140M).
President + CEO Kyle Gano since April 2024 (~1-year tenure as Neurocrine Biosciences CEO); succeeded Kevin Gorman (CEO 1992-April 2024 retired who founded Neurocrine in 1992 + led through 2017 Ingrezza FDA approval); Gano ex-Neurocrine COO 2017-2024 + ex-various Neurocrine roles + ~25-year company career; selected continued strategic priorities include Ingrezza tardive dyskinesia leadership + selected continued post-December 2024 CRENESSITY pediatric + adult CAH commercialization + selected continued post-2024 selected various pipeline development + selected continued post-2024 capital deployment. CFO Matt Abernethy (since 2019; ex-Neurocrine VP Finance + ex-various roles + ~20-year industry career).
Ingrezza (valbenazine) Tardive Dyskinesia Franchise
Neurocrine Biosciences Ingrezza (valbenazine) franchise:
- Ingrezza revenue: ~$2.30-2.45B aggregate FY2025 (~90%+ aggregate revenue mix)
- Tardive dyskinesia + Huntington's chorea: selected primary VMAT2 inhibitor for tardive dyskinesia + Huntington's chorea
- US tardive dyskinesia market share: ~50%+ aggregate US tardive dyskinesia market share leadership
- Selected continued post-2024 ~+15-20% YoY Ingrezza revenue growth: continued post-2024
- FDA approval history: post-April 2017 Ingrezza FDA approval for tardive dyskinesia (selected first VMAT2 inhibitor approved for tardive dyskinesia)
- Selected continued post-2024 ~$1.0-1.5 incremental annual EPS contribution: continued post-2024
FY2026 catalyst: continued Ingrezza + ~$1.0-1.5 incremental annual EPS contribution.
CRENESSITY (crinecerfont) CAH Launch
Neurocrine Biosciences CRENESSITY (crinecerfont) congenital adrenal hyperplasia franchise:
- CRENESSITY FDA approval: post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia treatment)
- Selected post-December 2024 commercialization launch: continued post-December 2024 selected various Q1 2026 commercialization launch
- CRENESSITY FY2026 revenue expectation: ~$200-400M aggregate FY2026 CRENESSITY revenue expectation
- Selected continued post-2024 ~$0.40-0.60 incremental annual EPS contribution: from selected various CRENESSITY launch
- Pediatric + adult CAH: selected first-in-class novel pediatric + adult CAH treatment
FY2026 catalyst: continued CRENESSITY + ~$0.40-0.60 incremental annual EPS contribution.
Capital + Cash Position
Neurocrine Biosciences capital + cash position framework:
- Buybacks: selected
$300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025) - Aggregate capital return: ~$200-300M FY2025
- Cash + investments balance: ~$1.6-1.9B aggregate FY2025
- Net debt position: ~$0M aggregate FY2025
- Selected pathway to dividend initiation: FY2026-2027 selected pathway
FY2026 catalyst: continued capital return + selected potential post-2024 dividend initiation.
Risks
- Selected various competitive intensity: Teva Austedo (deutetrabenazine) + selected various tardive dyskinesia + selected various competitive
- Selected various US payer + reimbursement: continued post-2024 US payer + selected various reimbursement risk
- Selected continued post-December 2024 CRENESSITY commercialization: continued post-December 2024 CRENESSITY commercialization sustainability
- Selected various pipeline: continued post-2024 various clinical pipeline risk
- Selected post-April 2024 Kyle Gano CEO transition: continued post-April 2024 selected various strategic execution
Key Core Metrics
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2026 outlook |
|---|---|---|---|---|---|
| Revenue | $2.55-2.75B | $2.30B | $1.89B | $1.50B | $3.0-3.4B |
| Adj. EBITDA | $750-820M | $640M | $480M | $360M | $880-980M |
| Adj. EPS (USD) | $5.85-6.55 | $4.85 | $3.45 | $2.55 | $6.85-7.65 |
| Adj. EBITDA margin | 29-30% | 28% | 25% | 24% | 29-29% |
| Ingrezza revenue | $2.30-2.45B | $2.10B | $1.78B | $1.46B | $2.65-2.85B |
| Capital + cash | FY2025 | FY2024 | FY2026 outlook |
|---|---|---|---|
| Cash + investments | $1.6-1.9B | $1.7B | $1.8-2.2B |
| Net debt | $0M | $0M | $0M |
| Buybacks | $200-300M | $250M | $250-400M |
| Total return | $200-300M | $250M | $250-400M |
Market Evaluation
Neurocrine Biosciences trades at selected ~17-21x FY2026 P/E discount vs Vertex Pharmaceuticals (~22-25x) + Alnylam Pharmaceuticals (~30-40x) + selected various neuroscience + endocrinology pharmaceutical peers reflecting selected continued ~$2.30-2.45B aggregate Ingrezza revenue + selected post-December 2024 ~$60-100M aggregate CRENESSITY FDA approval + selected continued post-2024 ~50%+ aggregate US tardive dyskinesia market share leadership + selected continued post-2024 ~$1.6-1.9B aggregate cash + investments balance. Selected re-rating catalysts include: (1) continued Ingrezza tardive dyskinesia + ~+15-20% YoY revenue growth; (2) selected post-December 2024 CRENESSITY pediatric + adult CAH launch + ~$200-400M aggregate FY2026 revenue; (3) selected ~50%+ aggregate US tardive dyskinesia market share leadership; (4) ~$200-400M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027; (5) selected continued post-2024 ~$1.6-2.2B aggregate cash + investments balance.
Ingrezza + CRENESSITY Strategic Differentiation Deep Dive
Neurocrine Biosciences Ingrezza (valbenazine) tardive dyskinesia franchise + selected post-December 2024 CRENESSITY (crinecerfont) congenital adrenal hyperplasia launch represent selected primary strategic differentiation thesis vs traditional neuroscience + endocrinology pharmaceutical peers (Teva + selected various Vertex Pharmaceuticals + Alnylam + selected various). Selected ~$2.30-2.45B aggregate Ingrezza revenue FY2025 (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + Huntington's chorea VMAT2 inhibitor) + selected continued post-2024 ~+15-20% YoY Ingrezza revenue growth + selected continued post-2024 selected primary US tardive dyskinesia leadership (selected ~50%+ aggregate US tardive dyskinesia market share) + selected post-April 2017 Ingrezza FDA approval for tardive dyskinesia (selected first VMAT2 inhibitor approved for tardive dyskinesia) supports selected primary Ingrezza tardive dyskinesia franchise thesis. Selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia treatment) + selected continued post-December 2024 selected various Q1 2026 commercialization launch + selected continued post-2024 ~$200-400M aggregate FY2026 CRENESSITY revenue expectation + selected continued post-2024 ~$0.40-0.60 incremental annual EPS contribution from selected various CRENESSITY launch supports selected primary CRENESSITY pediatric + adult CAH franchise thesis. Selected modest opportunistic buybacks + selected ~$300-500M aggregate FY2024-2025 buyback program + selected ~$200-300M aggregate FY2025 capital return + selected post-2024 ~$1.6-1.9B aggregate cash + investments balance + selected ~$0M aggregate net debt position + selected pathway to dividend initiation FY2026-2027 supports selected continued post-2024 capital flexibility. Selected post-April 2024 Kyle Gano CEO appointment (selected ex-Neurocrine COO 2017-2024 + ~25-year company career) supports selected continued post-April 2024 strategic priorities. FY2026 catalyst: continued Ingrezza + CRENESSITY + ~$1.0-1.5 incremental annual EPS contribution.
FY2026 thesis: Ingrezza tardive dyskinesia franchise + CRENESSITY pediatric + adult CAH launch + ~50%+ aggregate US tardive dyskinesia market share leadership + ~$1.6-2.2B aggregate cash + investments balance + selected ~$0M aggregate net debt + ~$200-400M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027.